News & Events

Home > News & Events > Content

Clinical Evaluation Of Ezetimibe

Shanghai Chiral Chemicals Inc | Updated: Jun 16, 2017

  Clinical evaluation of ezetimibe

  1 Ezetimibe alone was used in a randomized, double-blind trial of 190 patients with hypercholesterolemia compared to daily oral administration of ezetimibe 1,6,25,100,200,400 mg · kg- 1, continuous treatment of 8 weeks of efficacy, found that patients treated with ezetimibe plasma LDL-C dose-dependent decreased, compared with the baseline level, LDL-C decreased range of 0.6% -15.5%, total cholesterol The effects of ezetimibe l0mg · d-1 on plasma lipid in patients with primary hypercholesterolemia were significantly lower than those in control group (P <0.05). The results showed that LDI-C Level. The clinical efficacy of ezetimibe has a good safety and tolerance, and the best effect is l0mg · d-1, which can reduce LDL-C 18.5% and HDL-C 3.5 %, And showed a tendency to lower triglyceride (-4.9%).

  2 and statins combined with ezetimibe and various statins combined with pharmacodynamics and pharmacokinetic studies have also shown that: ezetimibe can be with statins or fibrates (such as fenofibrate ) To achieve better clinical efficacy. There are a number of scholars on ezetimibe and atorvastatin, pravastatin, lovastatin and simvastatin combined with the pharmacodynamic situation of the study found that ezetimibe and the above four drugs in combination, Have good synergistic effect, and the drug combination of good tolerance and safety, and its adverse reactions similar to placebo. Pharmacokinetics, ezetimibe on simvastatin and atorvastatin metabolism did not significantly affect. Because ezetimibe does not cause hyperacylglycerol disease in patients with disease progression, can be used alone can not tolerate other lipid-lowering drugs in patients, can also be used with statins can not tolerate high-dose statins patient. Clinical reports of ezetimibe adverse reactions slightly rare, more common is the allergic reaction, facial and glossopharyngeal edema, may cause breathing and dysphagia; sometimes rash, occasionally gastrointestinal discomfort and fatigue The In short, ezetimibe is a new type of cholesterol absorption inhibitors, with excellent pharmacological activity and safety, is the field of blood lipid pharmacological effects of a relatively new category, with a wide range of market prospects. Nevertheless, the long-term effects of ezetimibe on the morbidity and mortality of cardiovascular disease remain to be further examined in the future.